The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

The 11 patients were admitted to the hospital on 20, 21, and 22 January. "Now that their condition has improved and they are clinically stable, we are planning to taper the doses of Atropine under ...

Their ages ranged from 7 to 17 years and myopia ranged from 1.5 to 7.5 D. Patients received 0.125% atropine and did not discontinue the drugs for more then 10 days during the study period (3 years).

Treated with atropine, the patients showed unexpected recovery, and doctors are awaiting details on the toxin to ensure long-term protection. No new cases emerged in the past four days.